Read by QxMD icon Read

American Journal of Clinical Oncology

Jian Hou, Lugui Qiu, Yaozhong Zhao, Xuejun Zhang, Yan Liu, Zhao Wang, Fang Zhou, Yun Leng, Shifang Yang, Hao Xi, Fuxu Wang, Bing Zhu, Wenming Chen, Peng Wei, Xiangjun Zheng
OBJECTIVES: Circularly permuted tumor necrosis factor-related apoptosis-inducing ligand (CPT), or CPT, is a novel antitumor drug candidate. This phase 1b study evaluated the safety, tolerability, pharmacokinetics (PK), and efficacy of single-agent CPT in patients with relapsed or refractory multiple myeloma (RRMM), and aimed to identify the recommended dose for the phase 2 study. MATERIALS AND METHODS: Patients received single or multiple doses (once daily for 5 consecutive days per 21-d cycle) of CPT intravenous infusion at doses of 5, 6...
September 19, 2017: American Journal of Clinical Oncology
Ayumu Hosokawa, Takayuki Ando, Kohei Ogawa, Akira Ueda, Hiroki Yoshita, Hiroshi Mihara, Haruka Fujinami, Shinya Kajiura, Kazuhisa Yabushita, Naoki Horikawa, Yuka Kobayashi, Akira Yoshioka, Hideki Origasa, Toshiro Sugiyama
OBJECTIVES: To investigate the usefulness of S-1 plus cisplatin alternating with S-1 plus docetaxel as first-line treatment in patients with advanced gastric cancer, we conducted a phase I/II study to determine the maximum tolerated dose and recommended dose, and evaluate efficacy and toxicity. MATERIALS AND METHODS: Patients with histologically confirmed unresectable and recurrent gastric cancer were enrolled in this study. Cisplatin was administered on day 1 and the dose escalated by 10 mg/m from a starting dose of 40 mg/m in the phase I part...
September 19, 2017: American Journal of Clinical Oncology
Elizabeth Reznik, Andrew W Smith, Shoshana Taube, Justin Mann, Menachem Z Yondorf, Bhupesh Parashar, A Gabriella Wernicke
High-grade glioma is the most common primary brain tumor, with glioblastoma multiforme (GBM) accounting for 52% of all brain tumors. The current standard of care (SOC) of GBM involves surgery followed by adjuvant fractionated radiotherapy and chemotherapy. However, little progress has been made in extending overall survival, progression-free survival, and quality of life. Attempts to characterize and customize treatment of GBM have led to mitigating the deleterious effects of radiotherapy using hypofractionated radiotherapy, as well as various immunotherapies as a promising strategy for the incurable disease...
September 12, 2017: American Journal of Clinical Oncology
Stuart H Burri, Vinai Gondi, Paul D Brown, Minesh P Mehta
Glioblastoma (GBM) is a devastating brain tumor with poor prognosis despite advances in surgery, radiation, and chemotherapy. Survival of patients with glioblastoma remains poor, with only 1 in 4 patients alive at 2 years, and a 5-year survival rate of about 5%. Recurrence is nearly universal and, after recurrence, prognosis is poor with very short progression-free survival and overall survival (OS). Various salvage chemotherapy strategies have been applied with limited success. Tumor Treating Fields (TTFields) are a novel treatment modality approved for treatment of either newly diagnosed or recurrent GBM...
August 24, 2017: American Journal of Clinical Oncology
Lavanya H Palavalli Parsons, Brandon Roane, Dustin B Manders, Debra L Richardson, Siobhan M Kehoe, Matthew Carlson, David S Miller, Jayanthi S Lea
OBJECTIVE: Antivascular endothelial growth factor monoclonal antibodies inhibit tumor angiogenesis, consequently impeding the recruitment of new vasculature to existing and new tumor lesions. We sought to evaluate toxicities in women with recurrent cervical cancer after receiving bevacizumab combination chemotherapy. METHODS: A review was conducted of women with recurrent and metastatic cervical cancer who were treated with salvage chemotherapy with or without bevacizumab between 2005 and 2015...
August 16, 2017: American Journal of Clinical Oncology
John B Wilkinson, Peter Y Chen, Michelle F Wallace, Chirag S Shah, Pamela R Benitez, Alvaro A Martinez, Frank A Vicini
BACKGROUND: To report 6-year outcomes from a phase I/II trial using balloon-based brachytherapy to deliver APBI in 2 days. METHODS: A total of 45 patients with early-stage breast cancer received adjuvant APBI in 2 days with high-dose rate (HDR) brachytherapy totaling 2800 cGy in 4 fractions (700 cGy BID) using a balloon-based applicator as part of a prospective phase I/II clinical trial. All patients had negative margins and skin spacing ≥8 mm. We evaluated toxicities (CTCAE v3) as well as ipsilateral breast tumor recurrence (IBTR), regional nodal failure (RNF), distant metastasis, disease-free survival, cause-specific survival, and overall survival...
August 4, 2017: American Journal of Clinical Oncology
Jeffrey Meyer, Yull Arriaga, Joselin Anandam, Sirisha Karri, Samira Syed, Udit Verma, Abier Abdelnaby, Grace Raja, Ying Dong, Muhammad Beg, Glen Balch
OBJECTIVES: There is interest in improving the tumoricidal effects of preoperative radiotherapy for rectal carcinoma by studying new radiosensitizers. The safety and toxicity profile of these combination regimens needs rigorous clinical evaluation. The primary objective of this study was to evaluate the toxicity of combining bavituximab, an antibody that targets exposed phosphatidylserine, with capecitabine and radiation therapy. MATERIALS AND METHODS: Patients with stage II or III rectal adenocarcinoma were enrolled on a phase I study combining radiation therapy, capecitabine, and bavituximab...
July 31, 2017: American Journal of Clinical Oncology
Hiroko Machida, Aida Moeini, Marcia A Ciccone, Sayedamin Mostofizadeh, Tsuyoshi Takiuchi, Laurie L Brunette, Lynda D Roman, Koji Matsuo
OBJECTIVE: To examine survival outcomes of women with recurrent cervical cancer who received salvage chemotherapy with modified dose-dense paclitaxel (MDDP) monotherapy (paclitaxel 80 mg/m, administered on day 1, 8, and 15 without day 22). MATERIALS AND METHODS: A retrospective study was conducted to evaluate cause-specific survival after the first recurrence (SAR) of women with recurrent cervical cancer diagnosed between 2006 and 2014. Pooled analyses were performed to examine SAR in women who received MDDP monotherapy (n=17) for any treatment line, compared with those who received salvage chemotherapy with paclitaxel-doublet (n=18) and nonpaclitaxel regimens (n=52)...
July 31, 2017: American Journal of Clinical Oncology
Ann F Callahan, Michael White, Philip Ituarte, Singh Gagandeep, Yanghee Woo, Yuman Fong, Laleh Melstrom
INTRODUCTION: Gastric carcinoid is a rare entity with complex management options. This study aims to determine if surgical intervention in patients with local, regional, and metastatic gastric carcinoid is associated with prolonged survival. MATERIALS AND METHODS: The California Cancer Registry merged with the California Office of Statewide Health Planning and Development was queried for patients with a diagnosis of gastric carcinoid (2000 to 2011). Clinicopathologic characteristics, management, and outcomes were evaluated...
July 31, 2017: American Journal of Clinical Oncology
Francine E M Voncken, Rosa T van der Kaaij, Karolina Sikorska, Erik van Werkhoven, Jolanda M van Dieren, Cecile Grootscholten, Petur Snaebjornsson, Johanna W van Sandick, Berthe M P Aleman
OBJECTIVES: The objective of this study is to compare long-term outcomes between younger and older (70 y and above) esophageal cancer patients treated with curative intent. MATERIALS AND METHODS: Overall survival (OS), disease-free survival (DFS), and locoregional recurrence-free interval were compared between older (70 y and above) and younger (below 70 y) esophageal cancer patients treated between 1998 and 2013. Treatment consisted of neoadjuvant chemoradiotherapy with surgery or definitive chemoradiotherapy: 36 to 50...
July 31, 2017: American Journal of Clinical Oncology
Brandon M Huffman, Lisa A Kottschade, Patrick S Kamath, Svetomir N Markovic
OBJECTIVE: To report the clinical features, treatment, and outcomes of patients with immune checkpoint inhibitor-induced hepatotoxicity. PATIENTS AND METHODS: In this retrospective observational study, we identified patients with metastatic malignant melanoma seen in consultation and/or treated between March 2011 and March 2016. Hepatotoxicity was assessed using the Common Terminology Criteria for Adverse Events, v4.0. RESULTS: Seventeen patients were identified as having any degree of hepatotoxicity by history (grade 1 to 4)...
July 26, 2017: American Journal of Clinical Oncology
Patrick M Boland, Joshua E Meyer, Adam C Berger, Steven J Cohen, Tzahi Neuman, Harry S Cooper, Anthony J Olszanski, Monica Davey, Jonathan D Cheng, Abraham Lebenthal, Barbara A Burtness, Walter J Scott, Igor A Astsaturov
OBJECTIVES: Preoperative chemotherapy and radiation for localized esophageal cancer produces cure rates near 30% when combined with surgical resection. Vandetanib, a small molecule receptor tyrosine kinase inhibitor of VEGFR-2, VEGFR-3, RET, and EGFR, demonstrated synergy with radiation and chemotherapy in preclinical models. We conducted a phase I study to assess the safety and tolerability of vandetanib when combined with preoperative chemoradiation in patients with localized esophageal carcinoma who were surgical candidates...
August 2017: American Journal of Clinical Oncology
Margaret M Kozak, Rie von Eyben, Jonathan S Pai, Eric M Anderson, Mark L Welton, Andrew A Shelton, Cindy Kin, Albert C Koong, Daniel T Chang
OBJECTIVES: The prognostic value of several hematologic parameters, including platelet, lymphocyte, and neutrophil counts, has been studied in a variety of solid tumors. In this study, we examined the significance of inflammatory markers and their prognostic implications in patients with colorectal cancer (CRC). MATERIALS AND METHODS: Patients with stage I-III CRC who underwent surgical resection at the Stanford Cancer Institute between 2005 and 2009 were included...
August 2017: American Journal of Clinical Oncology
Peter Zavitsanos, Robert J Amdur, Peter A Drew, Kenneth Cusi, John W Werning, Christopher G Morris
OBJECTIVES: There is controversy about the prognosis of Hurthle cell carcinoma of the thyroid. The purpose of this project is to report the outcome of a well-defined group of patients treated at a single institution in the modern era. METHODS: Sixteen patients met the following inclusion criteria: Treatment with curative intent at our institution between January 1, 1997, and December 31, 2010. Primary treatment with total thyroidectomy with or without neck dissection...
August 2017: American Journal of Clinical Oncology
Tu D Dan, Harriet B Eldredge-Hindy, Jean Hoffman-Censits, Jianqing Lin, William K Kelly, Leonard G Gomella, Costas D Lallas, Edouard J Trabulsi, Mark D Hurwitz, Adam P Dicker, Robert B Den
PURPOSE/OBJECTIVES: Radium-223 is a first-in-class radiopharmaceutical recently approved for the treatment of castration-resistant prostate cancer in patients with symptomatic bone metastases. Initial studies investigating Radium-223 primarily used nonsteroidal first-generation antiandrogens. Since that time, newer antiandrogen therapies have demonstrated improved survival in patients with castration-resistant prostate cancer. It has been suggested that the rational combination of these newly approved agents with Radium-223 may lead to improved response rates and clinical outcomes...
August 2017: American Journal of Clinical Oncology
Stephen L Lewis, Sandro Porceddu, Naoki Nakamura, David A Palma, Simon S Lo, Peter Hoskin, Drew Moghanaki, Steven J Chmura, Joseph K Salama
PURPOSE: Stereotactic body radiotherapy (SBRT) is often used to treat patients with oligometastases (OM). Yet, patterns of SBRT practice for OM are unknown. Therefore, we surveyed radiation oncologists internationally, to understand how and when SBRT is used for OM. METHODS: A 25-question survey was distributed to radiation oncologists. Respondents using SBRT for OM were asked how long they have been treating OM, number of patients treated, organs treated, primary reason for use, doses used, and future intentions...
August 2017: American Journal of Clinical Oncology
Zhixin Sheng, Yanxia Zhang
OBJECTIVE: To determine the efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small cell lung cancer (NSCLC) patients with wild-type (WT) EGFR tumors, we performed an indirect meta-analysis to assess the treatment effects of EGFR-TKIs in such patients. METHODS: We searched for randomized controlled trials in Medline, Embase, the Cochrane controlled trials register, the Science Citation Index, and the American Society of Clinical Oncology annual meetings...
August 2017: American Journal of Clinical Oncology
Pierluigi Bonfili, Giovanni L Gravina, Francesco Marampon, Anna Rughetti, Mario Di Staso, Luigi Dell'Orso, Francesca Vittorini, Roberto Moro, Maria E La Verghetta, Silvia Parente, Marilisa Reale, Valeria Ruggieri, Pietro Franzese, Vincenzo Tombolini, Carlo Masciocchi, Ernesto Di Cesare
OBJECTIVES: In this active control trial, the rate of radio-induced WHO grade 3/4 oral mucositis and the change in quality of life, assessed by OMWQ-HN, were measured in subjects with head and neck cancer treated by platelet gel supernatant (PGS) and supportive medical treatment versus subjects treated by supportive medical treatment alone. MATERIALS AND METHODS: Eighty patients with nonmetastatic head and neck cancer underwent curative or adjuvant radiotherapy...
August 2017: American Journal of Clinical Oncology
Sarah N Hamilton, Ryan Carlson, Haroon Hasan, Shahrad R Rassekh, Karen Goddard
OBJECTIVES: The objective of this study was to determine treatment outcomes and long-term complications in pediatric patients with Ewing Sarcoma treated at the British Columbia Cancer Agency (BCCA). METHODS: A retrospective chart review of 101 pediatric patients (<19 y old) with Ewing Sarcoma diagnosed between 1960 and 2005 was performed. The Kaplan-Meier survival analysis and Cox regression multivariate analysis were used to assess prognostic factors for overall survival (OS) and event-free survival (EFS)...
August 2017: American Journal of Clinical Oncology
Lora S Wang, Elizabeth A Handorf, Hong Wu, Jeffrey C Liu, Clifford S Perlis, Thomas J Galloway
OBJECTIVES: Skin adnexal carcinoma (SAC) is a rare cutaneous malignancy that arises from sebaceous and sweat glands. These carcinomas are believed to behave more aggressively than cutaneous squamous cell carcinomas (SCC) with a propensity for local recurrence. The role of adjuvant radiotherapy in SAC is undefined. METHODS: We retrospectively reviewed all cases of head and neck SAC treated with surgery and adjuvant radiation from 2000 to 2012 at a single institution...
August 2017: American Journal of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"